Your Article Summary
See Latest ArticlesIntensified PEG-L-asparaginase and Antimetabolite-based Therapy for Treatment of Higher Risk Precursor-B Acute Lymphoblastic Leukemia
Journal of Pediatric Hematology/Oncology, 06/07/07
Salzer, W.L., et al. - The Pediatric Oncology Group 9203 pilot protocol was designed to determine the feasibility of delivering 29 biweekly doses of polyethylene glycol (PEG)-L-asparaginase, on a backbone of intensive multiagent antimetabolite-based consolidation and maintenance in higher risk B-precursor acute lymphoblastic leukemia. Between June 1992 and August 1993, 34 patients were enrolled on this limited institution pilot
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of pain management on sleep in preterm infants
European Journal of Pain, 12/18/09
Initial testing of topotecan by the pediatric preclinical testing program
Pediatric Blood & Cancer, 12/18/09
Safety and Transparency of Pediatric Drug Trials
Archives of Pediatrics and Adolescent Medicine, 12/18/09
Today in Pediatric Heme/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Duodenum-Sparing Technique of Head Resection in Solid Pseudopapillary Tumor of the Pancreas in Children
European Journal of Pediatric Surgery, 12/19/09
Fetal Brain Hemodynamic Changes in Intrauterine Transfusion: Influence of Needle Puncture Site
Fetal Diagnosis and Therapy, 12/19/09
Initial testing of topotecan by the pediatric preclinical testing program
Pediatric Blood & Cancer, 12/18/09